Inhibition of ␥-secretase, one of the enzymes responsible for the cleavage of the amyloid precursor protein (APP) to produce the pathogenic ␤-amyloid (A␤) peptides, is an attractive approach to the treatment of Alzheimer disease. In addition to APP, however, several other ␥-secretase substrates have been identified (e.g. Notch), and altered processing of these substrates by ␥-secretase inhibitors could lead to unintended biological consequences. To study the in vivo consequences of ␥-secretase inhibition, the ␥-secretase inhibitor LY-411,575 was administered to C57BL/6 and TgCRND8 APP transgenic mice for 15 days. Although most tissues were unaffected, doses of LY-411,575 that inhibited A␤ production had marked effects on lymphocyte development and on the intestine. LY-411,575 decreased overall thymic cellularity and impaired intrathymic differentiation at the CD4 ؊ CD8 ؊ CD44 ؉ CD25 ؉ precursor stage. No effects on peripheral T cell populations were noted following LY-411,575 treatment, but evidence for the altered maturation of peripheral B cells was observed. In the intestine, LY-411,575 treatment increased goblet cell number and drastically altered tissue morphology. These effects of LY-411,575 were not seen in mice that were administered LY-D, a diastereoisomer of LY-411,575, which is a very weak ␥-secretase inhibitor. These studies show that inhibition of ␥-secretase has the expected benefit of reducing A␤ in a murine model of Alzheimer disease but has potentially undesirable biological effects as well, most likely because of the inhibition of Notch processing.
Alzheimer disease (AD) 1 is the third most common cause of death and the leading cause of dementia in the United States (1) . Although the exact cause of AD is still unknown, the etiology of the disease is almost certainly linked to several neuropathological hallmarks observed in the brains of AD victims, particularly extracellular neuritic amyloid plaques and intracellular neurofibrillary tangles (2) (3) (4) . Although both of these neuropathological lesions probably contribute to progressive neuronal cell death in AD, the proximal lesion appears to be the amyloid plaques and their principal component, the A␤ peptides. A large body of evidence strongly suggests that overproduction, aggregation, and/or plaque deposition of the A␤ peptides, particularly A␤42, are central to the pathogenesis of AD (reviewed in Ref. 5) . In fact, two recent studies of patients immunized against the A␤42 peptide have provided the first preliminary clinical evidence that A␤ does indeed contribute to the cognitive decline in AD patients (6, 7) .
The A␤ peptides are produced by the sequential proteolytic cleavage of the amyloid precursor protein (APP) by ␤-and ␥-secretase. ␥-Secretase is a complex composed of at least four proteins, namely presenilins (presenilin 1 or -2), nicastrin, PEN-2, and APH-1 (8) . Presenilin 1 and -2 have been proposed to be the novel aspartyl proteases responsible for the catalytic activity of ␥-secretase (9, 10) . Because of the essential role of ␥-secretase in the generation of A␤ peptides, ␥-secretase inhibitors may be useful in the treatment of AD. To date, several ␥-secretase inhibitors have been identified that lower A␤ production in intact cells and cell-free systems (reviewed in Ref. 11) . In addition, two potent ␥-secretase inhibitors, N-[N- (3,5- difluorophenacetyl-L-alanyl)]-S-phenylglycine tert-butyl ester (DAPT) and LY-411,575, have also been shown to decrease A␤ production after administration to transgenic mice overexpressing human APP (12) (13) (14) .
It is appreciated now that APP is not the only substrate for ␥-secretase. Other proteins that have been shown to be substrates for ␥-secretase cleavage include Notch (16) and the Notch ligands Delta1 and Jagged2 (20) , ErbB4 (17) , CD44 (18) , and E-cadherin (19) . The cleavage of Notch by ␥-secretase has been studied most extensively. Notch plays an evolutionarily conserved role in regulating cell growth and lineage specification particularly during embryonic development (21) (22) (23) . Notch is activated by several ligands (Delta, Jagged, and Serrate) and is then proteolytically processed by a series of ligand-dependent and -independent cleavages. ␥-Secretase catalyzes the terminal cleavage event (S3 cleavage), which releases a fragment known as the Notch intracellular domain (NICD). The NICD fragment then translocates to the nucleus where it acts as a nuclear transcription factor (15, 24) . As expected from its role in Notch S3 cleavage, ␥-secretase inhibitors have been shown to block NICD production in vitro (25) . In vivo, Notch function appears to be critical for the proper differentiation of T and B lymphocytes (reviewed in Ref. 26) , and ␥-secretase inhibitors reduce the thymocyte number and block thymocyte differenti-ation at an early stage in fetal thymic organ cultures (27, 28) . These data suggest that in addition to their potential therapeutic benefit in AD, ␥-secretase inhibitors may have liabilities because of inhibition of the proteolytic processing of Notch (and other signaling molecules) that are critical for a variety of cellular functions.
Despite data clearly suggesting both the potential benefits and the liabilities of ␥-secretase inhibition, there are no published reports identifying the in vivo biological consequences of ␥-secretase inhibitors apart from the inhibition of APP processing and A␤ production. Such data are necessary to fully assess the strengths and liabilities of ␥-secretase inhibition as an approach to the treatment of AD. In this study, chronic treatment of mice with the potent ␥-secretase inhibitor LY-411,575 (13) was used to characterize the effects of ␥-secretase inhibition on A␤ production and to identify additional physiological consequences of ␥-secretase inhibition. A structurally related analogue that is a weak ␥-secretase inhibitor was used to distinguish effects of LY-411,575 that are due to ␥-secretase inhibition from the nonspecific effects of the compound.
EXPERIMENTAL PROCEDURES
Animals and Dosing-LY-411,575 and a diastereoisomer hereafter referred to as LY-D (see Fig. 1 ) were synthesized according to Wu et al. (29) . During synthesis, racemic 5-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one was coupled with tert-butoxycarbonyl-alanine, and the two diastereoisomers were separated by high pressure liquid chromatography. Each diastereoisomer was then deprotected with trifluoroacetic acid and subsequently condensed with the appropriate chiral 3,5-difluoromandelic acid to provide the expected products (see Fig. 1 ). The structures of LY-411,575 and LY-D were confirmed by nuclear magnetic resonance spectroscopy and tandem liquid chromatography-mass spectrometry. Both compounds were formulated as 10 mg/ml solutions in 50% polyethylene glycol, 30% propylene glycol, 10% ethanol and diluted in 0.4% methylcellulose for dosing.
TgCRND8 mice overexpress human APP with both the Swedish and Indiana familial AD mutations under the control of the Syrian hamster prion promoter (30) . TgCRND8 mice on a C57BL/6 ϫ C3H/He mixed genetic background were weaned, genotyped, and single-housed by the age of 4 -5 weeks. Six-week-old female TgCRND8 or male C57BL/6 mice (Charles River Laboratories) were dosed orally once/day for 5 or 15 days with 0.4% methylcellulose vehicle, 1-10 mg/kg LY-411,575, or 1-10 mg/kg LY-D. At the end of the dosing period, mice were sacrificed by CO 2 asphyxiation, total blood was collected from the posterior vena cava in EDTA Microtainer® tubes (BD Biosciences), and plasma was isolated. Cortices were surgically isolated from 1 hemibrain/mouse. Each cortex was homogenized in sucrose, extracted with guanidine, and sonicated (31) . Protein concentration was determined by the BCA assay (Pierce). All in vivo studies were approved by the Animal Care and Use Committee of the Schering-Plough Research Institute.
Cell Lines-HEK293 cells expressing human APP carrying both the Swedish and London mutations have been described previously (32) . Human Notch1 was cloned from human fetal brain cDNA (Clontech), and a truncated Notch1 construct lacking the extracellular EGF repeat domain was prepared (referred to as N⌬E) (15) . N⌬E was also stably expressed in HEK293 cells.
Assays for A␤ and NICD-Procedures for measuring ␥-secretase activity in membranes prepared from HEK293 cells expressing APP have been described previously (32) . Intact HEK293 cells expressing either APP or N⌬E were treated with various concentrations of LY-411,575 or LY-D for 4 h at 37°C. In the case of cells expressing N⌬E, cells were lysed, the cell lysates were separated on a 4 -12% NuPAGE gel, and the processed NICD fragment was detected via Western blot with a cleavage site-specific antibody. The inhibition of NICD production was quantified by spot densitometric analysis using FluorChem (Alpha Innotech Corp.). In the case of cells expressing APP, the conditioned medium was collected, centrifuged at 10,000 ϫ g for 5 min to remove cell debris, and stored at Ϫ20°C prior to the determination of A␤ levels. A␤40 and -42 produced in HEK293 membrane-and cell-based assays, as well as plasma A␤40 and cortex A␤40 from TgCRND8 mice, were analyzed without pretreatment using an electrochemiluminescence detection-based immunoassay (32) . Plasma A␤42 was measured by enzyme-linked immunosorbent assay as described previously (33) . A commercially available enzyme-linked immunosorbent assay kit (BioSource International) was used to measure cortex A␤42 according to the manufacturer's instructions.
Flow Cytometry-Single cell suspensions from the thymus and spleen were prepared from individual tissues in RPMI 1640 medium containing 10% fetal calf serum (Invitrogen) by passage through a 100-m nylon cell strainer (Falcon-BD Biosciences). Peripheral blood was collected as described above, and erythrocytes were lysed (erythrocyte lysis buffer, Sigma). Cells from the thymus, spleen, or blood were enumerated by trypan blue exclusion and then incubated for 20 min at 4°C in the dark with 5 g/ml Fc block (Pharmingen) and 300 g/ml purified mouse IgG in phosphate-buffered saline, 1% bovine serum albumin, 0.1% sodium azide to minimize nonspecific antibody binding. Fluorochrome-conjugated monoclonal antibodies to the following mouse surface markers were then added, and the incubation was continued for 20 min at 4°C in the dark: CD4 (GK1.5), CD8␣ (53-6.7), CD44 (IM7), CD25 (PC61), CD3 (145-2C11), ␣␤-TcR (H57-597), ␥␦-TcR (GL3), B220 (RA3-6B2), and IgM (R6-60.2) (all obtained from Pharmingen). Matched fluorochrome-conjugated isotype control antibodies were used to determine nonspecific binding. To determine viability, samples were stained subsequently with 5 g/ml propidium iodide (Calbiochem). Events were acquired on a FACSCalibur instrument (BD Biosciences Immunocytometry Systems) and analyzed with FlowJo software (Stanford University). The number of cells of each phenotype was determined by multiplying the percentage of cells in the population by the total number of thymus or spleen cells, as appropriate.
Histology-At the end of the dosing period the brain, thymus, spleen, liver, kidney, heart, stomach, adrenal glands, small intestine, large intestine, and lungs were collected in 10% neutral-buffered formalin, embedded in paraffin, and stained with hematoxylin and eosin for light microscopic examination. In addition, small and large intestine were stained with periodic acid-Schiff stain to highlight mucin-containing goblet cells. Comprehensive bone marrow smear cytologic examinations were also performed.
RESULTS

LY-411,575 Is a Potent ␥-Secretase Inhibitor in Vitro and in
Vivo-As reported previously (13) , LY-411,575 is a very potent ␥-secretase inhibitor in vitro as assessed by inhibition of A␤ production (IC 50 , 0.078 and 0.082 nM in membrane-and cellbased ␥-secretase assays, respectively (Fig. 1) ). LY-411,575 is also a potent inhibitor of Notch S3 cleavage (Fig. 1, IC sized ( Fig. 1) . Depending on the assay, LY-D is 180 -2000-fold less potent than LY-411,575 as an inhibitor of ␥-secretase (Fig.  1) . In vivo studies demonstrated that both 1 and 10 mg/kg oral doses of LY-411,575 decreased brain and plasma A␤40 and -42 robustly when chronically administered to TgCRND8 mice (Fig. 2) . In contrast, the administration of the less active diastereoisomer LY-D to TgCRND8 mice had no effect on A␤ levels in either the brain or plasma (Fig. 2) . The different in vivo activities of LY-411,575 and LY-D are not because of different pharmacokinetic properties, because the two compounds achieved similar plasma levels after oral administration (data not shown). These in vitro and in vivo data demonstrate that LY-411,575 and LY-D are excellent tools to distinguish the mechanism-based effects of ␥-secretase inhibition from the compound-related effects that are not due to ␥-secretase inhibition.
The time course of the effects of LY-411,575 on plasma and brain A␤40 levels is shown in Fig. 3 . A single oral dose of 10 mg/kg LY-411,575 rapidly decreased plasma A␤40 with the maximal effect being observed by 1 h after administration (Fig.  3A) . The reduction of plasma A␤ was still evident 24 h after the administration of LY-411,575 but returned to base-line levels by 48 h after administration (Fig. 3A) . LY-411,575 also substantially decreased guanidine-soluble brain A␤ levels, although the maximal effect was less pronounced, the time required to reach the maximal effect was longer, and the duration of the effect was longer than that seen for reduction of plasma A␤ (Fig. 3B ). These data demonstrate that dosing of LY-411,575 once/day is sufficient to maintain continual inhibition of ␥-secretase.
General in Vivo Effects of Chronic ␥-Secretase Inhibition-LY-411,575 and LY-D (1 and 10 mg/kg) were administered to Histopathological analysis demonstrated that neither LY-411,575 nor LY-D had any effect on the majority of the tissues examined, including the brain, liver, kidney, lungs, heart, adrenal glands, and stomach. Bone marrow smears also revealed no abnormalities (data not shown). In contrast, effects of LY-411,575 were observed in the thymus, spleen, and intestine. These observations are discussed individually below.
Chronic ␥-Secretase Inhibition Alters Lymphocyte Development-Chronic treatment of TgCRND8 mice with LY-411,575 induced a marked atrophy of the cortical zone of the thymus (Fig. 4, compare A with B) . This effect was dose-dependent and was consistent with the dose-dependent reduction in the absolute thymocyte cell number caused by LY-411,575 (Fig. 5A) . In contrast, LY-D had no effect on thymus histology (Fig. 4, compare A with C) or the absolute number of thymocytes (Fig. 5A) . Flow cytometric analysis of intrathymic populations revealed that the number and proportion of thymocytes defined by CD4/ CD8 expression was altered by treatment with LY-411,575 but not by treatment with LY-D. Consistent with the overall decrease in thymocyte number (Fig. 5A) , the absolute number of CD4 ϩ CD8 ϩ double positive, CD4 Ϫ CD8 Ϫ double negative (DN), CD4 ϩ single positive, and CD8 ϩ single positive cells also decreased in a dose-dependent manner (Fig. 5B) . However, the proportion of DN and single positive cells increased, whereas the proportion of double positive cells decreased (Fig. 5C) .
A detailed examination of the DN cell population demonstrated that LY-411,575 administration increased the relative percentage of the CD44 ϩ CD25 Ϫ and CD44 ϩ CD25 ϩ DN thymocytes while causing a commensurate decrease in the proportion of CD44
Ϫ CD25 ϩ and CD44 Ϫ CD25 Ϫ DN thymocytes (Fig. 5D ) indicating a block at a very early stage of intrathymic T cell development. Once again, these effects were not observed in LY-D-treated animals (Fig. 5D) . Interestingly, no differences in CD44 mean fluorescence intensity were observed across treatment groups implying that processing of this putative ␥-secretase substrate was unaffected by LY-411,575 treatment. The percentage of thymocytes expressing intermediate or high levels of CD3/␣␤-TcR was significantly reduced in accord with the inhibition of CD4/CD8 populations, although no consistent alterations in the percentage or number of ␥␦-TcR cells were noted. A slight increase in the proportion of thymic B220 ϩ B cells was observed in LY-411,575-treated animals, although this did not reach statistical significance (data not shown).
The effect of LY-411,575 treatment on peripheral leukocyte compartments was also examined. In contrast to the observations made in the thymus, neither LY-411,575 nor LY-D treatment significantly altered T cell populations in the peripheral (Fig. 7, B, E, and H) . In one mouse that was sacrificed in a moribund condition, LY-411,575 treatment (10 mg/kg) also caused epithelial erosion with underlying infiltration of inflammatory cells in the lamina propria (Fig. 7B, circled areas) , the accumulation of necrotic cell debris, and dilation of crypts (Fig. 7B, arrowheads) . In contrast, chronic treatment of TgCRND8 mice with 1 mg/kg LY-411,575 or with either dose of LY-D had no effect on the gastrointestinal tract (Fig. 7, C and F) .
DISCUSSION
Several recent reports (12-14) have described potent ␥-secretase inhibitors that are active in animal models of A␤ deposition. These studies suggest that ␥-secretase inhibitors will be appropriate tools to test the amyloid hypothesis of AD in humans and may ultimately have clinical utility in the treatment of the disease. It is recognized now that in addition to APP, ␥-secretase proteolytically processes several other substrates, most notably Notch (10). However, little is actually known about the biological consequences of blocking the processing of the myriad ␥-secretase substrates in vivo, particularly in adult organisms. To address this uncertainty, the biological effects of the potent ␥-secretase inhibitor LY-411,575 (13) were compared with the biological effects of LY-D, a structurally and pharmacokinetically related diastereoisomer of LY-411,575 that is significantly less potent as a ␥-secretase inhibitor. This comparison permits a definitive distinction between the biological effects of ␥-secretase inhibition and the biological effects of LY-411,575 that are unrelated to ␥-secretase inhibition.
In vitro, LY-411,575 inhibited A␤ and NICD production with similar potencies. It is therefore reasonable to assume that LY-411,575 similarly inhibits APP and Notch processing in vivo. Consistent with the potent inhibition of A␤ production in vitro, chronic treatment of TgCRND8 mice with 1-10 mg/kg LY-411,575 decreased plasma-and guanidine-soluble brain A␤40 and -42. The inhibitory effect of LY-411,575 on brain A␤ was consistently less pronounced and more delayed than the inhibitory effect of the drug on plasma A␤. This may reflect the fact that brain A␤, particularly A␤42, exists in an oligomeric, aggregated, or otherwise insoluble state and hence is cleared less rapidly than plasma A␤, which is likely to be largely soluble. In the case of brain A␤42, this may also reflect the fact that brain A␤42 levels in TgCRND8 mice are increasing during the course of these experiments, i.e. between 6 -8 weeks of age (30) . The degree of inhibition of plasma and brain A␤40 and -42 levels by chronic administration of LY-411,575 was consistent with the degree of inhibition seen in acute (single dose) studies ( Fig. 3 and data not shown) , suggesting that no compensatory up-regulation of ␥-secretase activity occurred during the time frame of these studies.
As assessed by histological examination and bone marrow cytology, chronic treatment of TgCRND8 mice with LY-411,575 or LY-D had no effect on a number of tissues including the brain, liver, kidney, lung, heart, adrenal gland, bone marrow, and stomach. This suggests that the high levels of APP and ␥-secretase in some tissues (e.g. brain and lung 2 ) may be functionally redundant. In contrast, dose-dependent effects of chronic treatment of mice with LY-411,575 were observed in the thymus, spleen, and intestine. LY-411,575 treatment induced a profound atrophy of the cortical region of the thymus with a significant depletion of the cortex, a pronounced dosedependent decrease in overall thymic cellularity, and an overall reduction in each of the major intrathymic populations defined by CD4 and -8. These effects of LY-411,575 are clearly due to ␥-secretase inhibition, because they were not seen following chronic treatment with the structurally related diastereoisomer LY-D. Further analysis of the DN compartment in LY-411,575-treated animals revealed a significant increase in the proportion of cells in the CD44 ϩ CD25 Ϫ and CD44 ϩ CD25 ϩ subpopulations and a corresponding reduction in the proportion of cells in the CD44
Ϫ CD25 ϩ and CD44 Ϫ CD25 Ϫ subpopulations. These data strongly suggest that LY-411,575 treatment results in a specific developmental blockade of intrathymic differentiation at the step at which CD44 ϩ CD25 ϩ cells differentiate to CD44
Ϫ CD25 ϩ cells. These results are generally consistent with the in vitro effects of ␥-secretase inhibitors on thymocyte maturation observed in fetal thymic organ cultures (27, 28, 35) and with the in vivo effects seen after inactivation of the Notch1 gene (34), although these earlier reports localized the block at the preceding differentiation step (CD44 ϩ CD25 Ϫ and CD44 ϩ CD25 ϩ ). Differences in the affinity and selectivity of the ␥-secretase inhibitor employed or differences between chronic in vivo administration and short term in vitro treatment of fetal thymic organ cultures with ␥-secretase inhibitors may account for this discrepancy. Overall, these data suggest that altered Notch activity is responsible for the effects of LY-411,575 on the thymus, although it is not possible to specifically determine which ␥-secretase substrate(s) involved in Notch signaling is/are affected (Notch, Jagged, and/or Delta) (36) . A contribution of altered E-cadherin (37, 38) or CD44 (39) processing to this altered intrathymic differentiation is possible as well, although no effect of LY-411,575 on CD44 expression in the thymus was observed.
LY-411,575 treatment also exerted profound effects on B cell development. Following LY-411,575 administration, a slight increase in the percentage of B lineage cells in the thymus (as defined by expression of B220) was consistently observed, although this was not statistically significant. This implies that in vivo ␥-secretase inhibition may alter B versus T cell lineage decisions within the earliest uncommitted lymphocyte stem cell populations in the thymus, as suggested previously (28, 34, 46) . More strikingly, LY-411,575 significantly inhibited splenic B cell maturation and correspondingly increased the number of immature B cells in the blood despite having no overall effect on splenic cellularity or on other spleen cell populations. LY-D treatment did not cause these effects. These data suggest an important role for ␥-secretase in B cell development in the spleen. Several recent reports (40 -42) suggest that Notch signaling plays a role in marginal zone B cell development in the spleen, although no effect on the peripheral B cell compartment was reported in Notch1-deficient mice (34) . Therefore, the elevation in immature B cells in spleen tissues following treatment with LY-411,575 may also be because of inhibition of Notch or Notch ligand processing via ␥-secretase.
Chronic treatment of TgCRND8 mice with LY-411,575 also caused profound changes in the gastrointestinal tract. Specifically, LY-411,575 induced a proliferation of mucin-producing goblet cells, a corresponding increase in mucin detected in the lumen of the intestine, and, in one animal, mild crypt necrosis and erosion of the intestinal epithelium with accumulation of cellular debris in the intestinal lumen. These effects of LY-411,575 are clearly because of inhibition of ␥-secretase activity, because they were not observed in animals treated with LY-D. It was reported recently (43) that a structurally related ␥-secretase inhibitor induced similar effects in rat intestine. The effects of LY-411,575 on the intestine are probably also because of the inhibition of Notch processing by ␥-secretase. Indeed, mouse embryos deficient in Hairy/Enhancer of split-1 (Hes-1), which is a transcriptional repressor protein that is intimately involved in Notch signaling, have a very similar phenotype in the gastrointestinal tract (44) . It is likely that the decrease in body weight and increase in mortality in TgCRND8 mice treated with LY-411,575 are because of the effects of the compound on the intestine. It also remains possible, however, that subtle alterations in the mucosal immune response might play a role in these findings.
The present study demonstrates the ability of ␥-secretase inhibitors to chronically reduce A␤ production. Longer treatment with LY-411,575 (13) and several reports of anti-A␤42 immunization of mice and humans suggest that chronic reduction of A␤ production also allows clearance of amyloid plaques and improvement of cognitive function (6, 7) . Taken together, these data suggest that ␥-secretase inhibitors offer substantial promise for the treatment of AD. However, the present study also shows that ␥-secretase inhibitors have several potential liabilities that may limit this promise. Some of these potential liabilities may be tolerable. For example, the effect of LY-411,575 on intrathymic T cell development may not be a major issue in the elderly, because the thymus normally atrophies extensively by early adulthood (45) . Nevertheless, further assessment of these potential liabilities would be informative. For example, it will be important to measure functional T and B cell responses after ␥-secretase inhibitor treatment to more fully assess the effect of ␥-secretase inhibition on the function of the immune system. In any case, these studies suggest caution in the testing of ␥-secretase inhibitors in humans and indicate specific side effects that should be monitored in any future clinical trials.
